Literature DB >> 31786713

Epidemiology and diagnosis of pulmonary embolism in lung cancer patients: is there a role for age adjusted D-dimers cutoff?

I Anagnostopoulos1, S Lagou2, M K Spanorriga2, K Tavernaraki3, G Poulakou2, K N Syrigos2, L Thanos3.   

Abstract

Our knowledge about the incidence of pulmonary embolism (PE) and the performance of age adjusted D-dimers (Dd) cutoff amongst patients with lung cancer (LC) and suspected PE, remains limited. We retrospectively analyzed all clinically suspected patients who underwent computed tomography pulmonary angiography (CTPA) in a tertiary hospital during a 19 month period. Cancer diagnosis was established using ICD10 code. Eligible for Dd analysis were those tested up to 24 h prior to the scan. We analyzed 2549 patients (54.6% males, median age 68.8 years, IQR 57-78), 15.8% had active LC and 5.4% other cancers (oC), while 70% were scanned in the Emergency Department (ED) and the rest during hospitalization. Overall incidence of PE was 16%. LC, but not oC, increased significantly the risk for PE (OR 1.58, 95% CI 1.21-2.06). LC patients were less likely to have bilateral (aOR 0.16, 95% CI 0.07-0.4) or central PE (aOR 0.2, 95% CI 0.09-0.48). Amongst those diagnosed with PE in the ED, LC increased all-cause inhospital mortality (aOR 6.7, 95% CI 2.64-16.95). When age adjusted instead of conventional Dd cutoff was used for ruling out PE in the ED, specificity for LC patients increased (10.16% vs 3.91%) without false negative tests (negative likelihood ratio-NLR = 0). A higher cutoff of 1.13 mg/l raised specificity to 28.9%, with only one case missed (sensitivity: 97.4%, NLR: 0.09, 95% CI 0.01-0.64). LC increases the risk for PE and adversely affects prognosis. Age adjusted and probably an even higher, "LC adjusted" Dd cutoff, could increase the specificity of the test without compromising its sensitivity.

Entities:  

Keywords:  D-dimers; Diagnosis; Lung cancer; Pulmonary embolism

Mesh:

Substances:

Year:  2020        PMID: 31786713     DOI: 10.1007/s11239-019-02003-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  24 in total

1.  Embolus location affects the sensitivity of a rapid quantitative D-dimer assay in the diagnosis of pulmonary embolism.

Authors:  Wouter De Monyé; Bernd-Jan Sanson; Melvin R Mac Gillavry; Peter M T Pattynama; Harry R Büller; Annette A van den Berg-Huysmans; Menno V Huisman
Journal:  Am J Respir Crit Care Med       Date:  2002-02-01       Impact factor: 21.405

2.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers.

Authors:  Helen K Chew; Theodore Wun; Danielle Harvey; Hong Zhou; Richard H White
Journal:  Arch Intern Med       Date:  2006-02-27

3.  Prognosis of cancers associated with venous thromboembolism.

Authors:  H T Sørensen; L Mellemkjaer; J H Olsen; J A Baron
Journal:  N Engl J Med       Date:  2000-12-21       Impact factor: 91.245

4.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.

Authors:  John A Heit; W Michael O'Fallon; Tanya M Petterson; Christine M Lohse; Marc D Silverstein; David N Mohr; L Joseph Melton
Journal:  Arch Intern Med       Date:  2002-06-10

Review 5.  Epidemiology of cancer-related venous thromboembolism.

Authors:  Ted Wun; Richard H White
Journal:  Best Pract Res Clin Haematol       Date:  2009-03       Impact factor: 3.020

6.  Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.

Authors:  Alok A Khorana; Charles W Francis; Eva Culakova; Nicole M Kuderer; Gary H Lyman
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

7.  National Trends in Pulmonary Embolism Hospitalization Rates and Outcomes for Adults Aged ≥65 Years in the United States (1999 to 2010).

Authors:  Karl E Minges; Behnood Bikdeli; Yun Wang; Nancy Kim; Jeptha P Curtis; Mayur M Desai; Harlan M Krumholz
Journal:  Am J Cardiol       Date:  2015-08-14       Impact factor: 2.778

8.  Clinical presentation and in-hospital death in acute pulmonary embolism: does cancer matter?

Authors:  Franco Casazza; Cecilia Becattini; Eliana Rulli; Ilaria Pacchetti; Irene Floriani; Marco Biancardi; Angela Beatrice Scardovi; Iolanda Enea; Amedeo Bongarzoni; Luigi Pignataro; Giancarlo Agnelli
Journal:  Intern Emerg Med       Date:  2016-03-29       Impact factor: 3.397

9.  Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study.

Authors:  Marc Righini; Josien Van Es; Paul L Den Exter; Pierre-Marie Roy; Franck Verschuren; Alexandre Ghuysen; Olivier T Rutschmann; Olivier Sanchez; Morgan Jaffrelot; Albert Trinh-Duc; Catherine Le Gall; Farès Moustafa; Alessandra Principe; Anja A Van Houten; Marije Ten Wolde; Renée A Douma; Germa Hazelaar; Petra M G Erkens; Klaas W Van Kralingen; Marco J J H Grootenboers; Marc F Durian; Y Whitney Cheung; Guy Meyer; Henri Bounameaux; Menno V Huisman; Pieter W Kamphuisen; Grégoire Le Gal
Journal:  JAMA       Date:  2014-03-19       Impact factor: 56.272

10.  D-dimer level is related to the prognosis of patients with small cell lung cancer.

Authors:  Xuqin Jiang; Xiaodong Mei; Huimei Wu; Xiaojuan Chen
Journal:  Ann Transl Med       Date:  2017-10
View more
  2 in total

1.  Characteristics and outcomes of cancer patients who develop pulmonary embolism: A cross-sectional study.

Authors:  Serafeim Chlapoutakis; Vasiliki Epameinondas Georgakopoulou; Nikolaos Trakas; Georgios Kouvelos; Petros Papalexis; Christos Damaskos; Pagona Sklapani; Anastasios Grivas; Panagiotis Gouveris; Dimitrios Tryfonopoulos; Alexandros Tzovaras; Gerasimos Ardavanis-Loukeris; Elissavet Grouzi; Demetrios A Spandidos; Miltiadis Matsagkas
Journal:  Oncol Lett       Date:  2022-04-04       Impact factor: 3.111

2.  The diagnostic value of D-dimer with simplified Geneva score (SGS) pre-test in the diagnosis of pulmonary embolism (PE).

Authors:  Zhihui Fu; Xibin Zhuang; Yueming He; Hong Huang; Weifeng Guo
Journal:  J Cardiothorac Surg       Date:  2020-07-20       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.